ESR2 and breast cancer: Furthermore, previous studies from our laboratory using BC cell lines have demonstrated the antiproliferative effects of SM6Met via a mechanism involving the selective ER subtype modulating (SERSM) action of SM6Met, by specifically demonstrating that SM6Met acts as an ERβ agonist and an ERα antagonist (Visser et al., 2013).